%0 Journal Article
%T [Argentine consensus on the diagnosis and therapeutics of treatment resistant schizophrenia].
%A Corrales A
%A Vilapriño Duprat M
%A Benavente Pinto C
%A Garay C
%A Corral R
%A Gargoloff PR
%A Goldchluk A
%A Hönig G
%A Jufe G
%A Lamaison F
%A Leiderman EA
%A Morra C
%A Rebok F
%A Gargoloff PD
%J Vertex
%V 0
%N 154
%D 12 2021
%M 35041733
暂无%X Approximately 30% of people with schizophrenia fail to respond to first-line antipsychotic treatment which impacts the burden of the disease. Treatment-resistant schizophrenia (TRS) denotes patients with failure to respond to at least two adequate trials of different antipsychotics. Clozapine is a unique drug approved for treating treatment-resistant schizophrenia, however 1/3 of patients fail to respond to clozapine. Even though different strategies have been proposed for treating clozapine-resistant schizophrenia, the evidence is very limited, unclear, and of poor quality. A formal literature search was conducted and then, panel members were asked to complete 35 questions addressing different aspects of TRS. A modified Delphi method was used to unify expert opinion and achieve consensus. The expert consensus in diagnostic and treatment of TRS is the result of experts from the main national scientific societies under the organization of the Argentine Association of Biological Psychiatric (AAPB). The consensus statement aims to guide on diagnosis and treatment.